表在性膀胱癌の再発予防に対するピラルビシン術後早期短時間連日膀胱内注入療法

Intravesical instillation of pirarubicin in prophylactic treatment following TUR for superficial bladder cancer―Five minutes retaining,seven consecutive days administration

表在性膀胱癌26例に対するTUR後の再発予防を目的として，ピラルビシン（THP）30mgを生食50mlに溶解し，術翌日から連日7日間5分間貯留を行った。コントロールとしてTURのみの37例と非再発率を比較した。THP注入群の非再発率は1年83.7％，2年67％，コントロール群は1年77.6％，2年54.6％で統計学的に有意差は認められなかった。しかし多発腫瘍例では，THP注入により再発予防効果が認められた。THP注入による膀胱刺激症状の副作用は26例中3例（11.5％）と少なく，THP術後早期連日短時間注入療法は安全で有効な治療法であることが示された。

We evaluated the prophylactic effect of intravesical instillation of pirarubicin（THP）following transurethral resection（TUR）for superficial bladder cancer. A total of 26 patients were administered 30mg of THP dissolved in 50ml of normal saline,retained for 5minutes in the bladder for 7 consecutive days from the first day after TUR. The recurrence-free rate of THP administration group determined by Kaplan-Meyer analysis were compared to control group,a total of 37 patients treated with only TUR. The one-year and two-year recurrence-free rate of THP administration group was 83.7％,67％ and that of control group was 77.6％,54.6％（statistically not significant）respectively. But the prophylactic efficacy of THP instillation was found in the patients with multiple bladder tumors. Adverse reactions were observed in 3 patients（11.5％）and all of them were irritable bladder symptoms. We concluded that intravesical instillation of THP retained for 5minutes,for 7 consecutive days was safe and effective therapy.